Home  /  Resource Library  /  Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long term follow-up of the phase I/II AU-003 study

Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long term follow-up of the phase I/II AU-003 study

Long term results of a study investigating zanubrutinib for first line treatment of CLL.